CapsulesClinical Overview
Esomeprazole (40mg enteric-coated) and Levosulpiride (75mg sustained-release) combines an S-isomer proton pump inhibitor with a central/peripheral prokinetic benzamide. Esomeprazole exerts long-lasting suppression of basal and meal-stimulated gastric acid secretion. Levosulpiride selectively blocks enteric D2 receptors and stimulates 5-HT4 receptors, dramatically improving gastric accommodation and antral motility. Indicated for severe GERD, refractory non-ulcer dyspepsia, and gastroparesis.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally once daily, 30 to 60 minutes before breakfast with a glass of water. Swallow whole.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Somnolence, fatigue, amenorrhea, galactorrhea, gynecomastia, headache, abdominal distress. Rare/Severe: Extrapyramidal syndromes (tremor, dystonia), tardive dyskinesia, neuroleptic malignant syndrome, and hyperprolactinemia.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Contraindicated in gastrointestinal bleeding, mechanical obstruction, pheochromocytoma, and convulsive disorders. Avoid concomitant central depressants or alcohol. Exercise caution in elderly patients.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or gastrointestinal treatment recommendations. Always consult a registered gastroenterologist or qualified medical practitioner before initiating, altering, or discontinuing any gastrointestinal medication or digestive therapy.
Esomeprazole 40mg (Enteric-Coated) + Domperidone 30mg (Sustained Release) Capsules
Esomeprazole (40mg enteric-coated) and Domperidone (30mg sustained-release) combines the pure S-enantiomer of omeprazole with an antiemetic prokinetic. Esomeprazole provides superior bioavailability and acid suppression compared to racemic omeprazole by undergoing lower first-pass hepatic metabolism via CYP2C19. Domperidone provides dopamine D2 receptor antagonism, enhancing lower esophageal sphincter tone and gastroduodenal transit. Indicated for erosive reflux esophagitis, GERD poorly responsive to standard acid suppression, and diabetic gastroparesis with nausea.
Pantoprazole 40mg (Enteric Coated) + Levosulpiride 75mg (Sustained Release) Capsules
Pantoprazole (40mg enteric-coated) and Levosulpiride (75mg sustained-release) is a potent combination of a proton pump inhibitor and a prokinetic benzamide. Pantoprazole profoundly suppresses gastric acid synthesis by blocking H+/K+-ATPase pumps. Levosulpiride is the levorotatory enantiomer of sulpiride that selectively antagonizes dopamine D2 receptors in the enteric nervous system and acts as an agonist at 5-HT4 receptors, accelerating gastric and gallbladder emptying and improving antropyloric coordination. Indicated for severe GERD refractory to conventional prokinetics, diabetic gastroparesis, and functional dyspepsia with prominent postprandial distress syndrome.
Esomeprazole Tablets 40 mg
Omeprazole Gastro-Resistant Capsules (20mg) is a prototypical proton pump inhibitor on the WHO Model List of Essential Medicines. It enters parietal cell canaliculi as a prodrug where acidic pH converts it to a tetracyclic sulfenamide that permanently inactivates H+/K+-ATPase pumps. Indicated for duodenal ulcers, benign gastric ulcers, reflux esophagitis, maintenance therapy of healed erosive esophagitis, and H. pylori eradication (as part of triple therapy).
Levosulpiride Tablets 25mg
Levosulpiride Tablets (25mg, 50mg, 75mg) is the pure levorotatory (S)-enantiomer of sulpiride, acting as a selective dopamine D2 receptor antagonist and 5-HT4 receptor agonist. In the gastrointestinal tract, it increases lower esophageal sphincter tone and accelerates gastric emptying; centrally, it modulates mood and relieves visceral pain. Indicated for functional dyspepsia (postprandial distress syndrome), diabetic gastroparesis, and gastroesophageal reflux disease unresponsive to standard prokinetics.